DESCRIPTION
Innate immune factors play a critical role in initiating and shaping adaptive immune responses and this is as true for the immune response against autoantigens and transplanted organs as it is for responses against microbial antigens. Research in this section encompasses a diverse set of projects, united by the underlying theme of investigating the importance of innate factors in transplantation, autoimmune renal disease and urological malignancies. The ambition of all the research in this area is to translate this knowledge into new and innovative therapies for clinical application.
The Innate Immunity Section includes research groups working on the following research areas:
Associated research programmes
Associated staff research interests
Tel:
020 7188 5880
Fax:
020 7188 5660
Email:
Interests:
The complement system has long thought to be a primitive “stop-gap” measure used to slow down infection until the more sophisticated adaptive immune system can undertake its highly potent attacks using antibodies and cells tailored to the specific target. It has become clear how simplified this view had been: the successful immune defense is now seen as a complex process in which the innate part plays vital roles in the instruction of adaptive immunity.
My research focuses on a novel crosstalk between the complement system, specifically the complement protein CD46, and T cell responses as CD46 signaling induces the development of IL-10-secreting adaptive regulatory T cells (Tregs).
We propose that understanding the underlying mechanisms that shape this novel important interplay between the complement system and T cells would significantly advance our ability to develop more effective immunotherapies to control T cell-mediated disease conditions. Thus, I intend to build a research program aimed at elucidating the role of complement-induced Tregs in normal immune homeostasis and states of chronic inflammation such as autoimmunity or pathogen persistence.
Tel:
02071888706
Fax:
02071885660
Email:
Website:
Interests:
Glomerulonephritis is a common cause of irreversible renal failure leading to the need for dialysis and transplantation. We aim to discover the fundamental causes of these diseases, in addition to the mechanisms that mediate renal inflammation. Our basic research program has used experimental models of glomerulonephritis to explore these mechanisms. In recent years we have dissected the role of the innate immune system and in particular how Toll-like receptors interact with the adaptive immune system and lead to tissue damage. We have also explored the role of specific IgG subclasses and Fc receptors in glomerular inflammation.
We are currently developing a specific interest in one form of glomerulonephritis, namely anti-neutrophil cytoplasmic antibody associated vasculitis (AAV). The figure below shows a glomerulus that has undergone fibrinoid necrosis and crescent formation, as would be seen in AAV. We are pursuing research based both on experimental models of AAV and on patient samples. Myeloperoxidase (MPO) is one of the major autoantigens in AAV and a model of AAV based on the knockout mouse has been published by others. We are using both this model and other novel systems to dissect both the mechanisms of capillary injury and the origin of autoimmunity in AAV. We are also collecting blood samples from newly presenting patients with AAV in order to examine how their white blood cells differ from controls, and to develop new markers of disease activity.
Tel:
020 7188 6768
Fax:
020 7188 5660
Email:
Website:
Interests:
The Protein Therapeutics Laboratory is a part of the Department of Nephrology and Transplantation and is also a constituent unit of the MRC Centre for Transplantation. The objective of the PTL is to discover and carry out translational research on novel protein and peptide therapeutic agents in the general areas of immunology and inflammatory disease but with a special emphasis on therapies that can have a near-term impact on transplantation outcomes. The PTL has developed a novel and generic protein engineering technology termed cytotopic modification which enables soluble proteins or peptides to bind to cell surfaces. This approach enables organs to be perfused with engineered proteins prior to transplantation so that both innate and adaptive immune responses can be manipulated within the transplanted organ rather than through systemic treatment of the organ recipient. One agent using this technology has entered pilot clinical studies in renal transplantation . The laboratory has research collaborations with a number of academic groups in the UK and elsewhere and these include an active programme with the imaging group at KCL. The PTL will also develop relationships with biotechnology and pharmaceutical companies to assist translation of its agents to the clinic.
Tel:
020 7188 5669
Fax:
0207 188 5660
Email:
Website:
Interests:
The laboratory has an interest in the structure and function of HLA alleles and their polymorphism. I have a general interest in human MHC genes and protiens. This is related to transplantation and the association between HLA and disease.This is based on the critical role of HLA as the pivotal point for all immune responses, not least through its role in shaping the T cell repertoire. Much of the routine transplantation work of the laboratory revolves around HLA specific antibody characterisation, and the facilitation and monitoring of its removal. The role of HLA as a ligand for natural killer cells has lead to an interest in KIR and other NK receptors and their role in the immune response.
Tel:
020 7188 1534
Email:
Website:
Interests:
Complement in transplantation and renal diseases.
Tel:
020 7188 5669
Fax:
020 7188 5660
Email:
Website:
Interests:
Dr Zhou is currently interested in the role of complement in immune regulation and trying to understand whether and how complement interacts with several pivotal cells of the immune system (e.g. antigen presenting cells, natural killer cells, mast cells and stem cells) participating in antimicrobial defence, cancer elimination, ischaemia/reperfusion injury, transplant rejection, autoimmunity and tissue remodelling. Understanding of the interaction between complement and these cells may lead to the development of new (complement-based) pharmaceutical approaches
Tel:
020 7188 1528
Fax:
020 7188 5660
Email:
Website:
CONTACTS FOR FURTHER INFORMATION
Dr Jill Holliday
Email
Website